CTOs on the Move

Dent Neurologic Institute

www.dentinstitute.com

 
The DENT Neurologic Institute is among the largest, most comprehensive neurology practices in the United States. We are focused on providing superior clinical care, advanced diagnostic services, clinical research, and education.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Novabay

We are passionate about improving people`s daily lives by offering clinically proven solutions to common skin and eye care problems through digital channels, traditional domestic retailers, and international distributors. We are in the process of growing from a small single-product company into a profitable mid-sized multi-product company. Our leading product, Avenova®, is the only lid & lash solution that brings eyes back to life by setting the highest standards of purity and efficacy. We pioneered the use of hypochlorous acid in the eyecare space and intend on making Avenova a household name. Our motto is, “If you have eyes, you need Avenova!” We also recently acquired DERMAdoctor, LLC, a skincare company offering more than 30 dermatologist-developed skincare products. We plan to launch nine new products this year with the founder of DERMAdoctor doing well known media placements such as QVC.

Aphria Incorporated

Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible.

Kowa Pharmaceuticals America

Kowa Pharmaceuticals America is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vishay BLH

BLH provides precision load cells, weight and force measurement systems, strain gages, web tension transducers, and instrumentation

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.